Datametrex Ai Li Stock Price, News & Analysis

Datametrex AI (OTC:DTMXF) announced the immediate appointment of Mr. Enrico Moretti to its Board of Directors, effective October 24, 2025. Mr. Moretti is a securities lawyer with cross-border experience (called to the Ohio bar in 1997 and Ontario bar in 2000) and specializes in corporate and securities law, corporate finance transactions, governance, and regulatory compliance.

The appointment fulfills the Exchange's minimum director requirement and follows a trading halt the Exchange imposed while the company remedied the board deficiency. The company said it acted promptly, has notified the Exchange, and is working to restore normal trading and confirm continued listing compliance.

Datametrex AI (OTC:DTMXF) announced plans to upsize its previously announced non-brokered private placements. The company seeks to increase its common shares placement from $3 million to $4 million, and its subscription receipts offering from $1 million to $1.3 million.

The subscription receipts proceeds will fund the integration of Yuzu Payment Solution into Datametrex's technology division, pursue merchant opportunities, and provide working capital. The company may pay up to 10% finder's fees in cash and warrants for both offerings. All securities will have a four-month plus one-day hold period.

Datametrex AI (OTC:DTMXF) has confirmed the terms of two previously announced private placement financings. The company is conducting a non-brokered private placement of up to $3,000,000 in common shares and another private placement of up to $1,000,000 in subscription receipts.

Both offerings are priced at $0.08 per share/receipt. The subscription receipts' proceeds will fund the integration of Yuzu Payment Solution in Datametrex's technology division and pursue merchant opportunities. The company may pay finder's fees of up to 10% cash and 10% finder's warrants for the financings, though no finder's fees apply to the Yuzu acquisition.

Datametrex AI Limited (DTMXF) has signed a non-binding Letter of Intent to acquire the Yuzu payment processing solution from Firstpayment Inc. for approximately $5.5 million through the issuance of 55 million shares at $0.10 per share.

The Yuzu Payment Solution includes 8 US patents and 2 Canadian patents for cryptocurrency payment processing, enabling merchants to conduct secure crypto transactions. The acquisition includes Firstpayment's intellectual property and patents under the "YUZU" trademark. Following the acquisition, Firstpayment's CEO Michael Kron is expected to join Datametrex's management team and board.

The deal is subject to TSXV approval and includes a planned $1 million non-brokered private placement of subscription receipts. Firstpayment's unaudited financials show intangible assets of $2.3 million as of June 30, 2025, with the company having incurred a net loss of $254,546 for the previous 12 months.

Datametrex AI (OTCQB:DTMXF) has requested an extension from the TSX Venture Exchange for closing its previously announced non-brokered private placement. The company expects to complete the process and file final documentation by August 11, 2025.

The proceeds will fund the expansion of healthcare product offerings and relocation of two healthcare clinics. The placement may include finders' fees of up to 10% cash and 10% broker warrants. All issued securities will have a four-month and one-day hold period per Canadian securities laws.

Datametrex AI Limited announced a non-brokered private placement financing of up to $3 million through an offering of up to 37.5 million Common Shares at $0.08 per share. The proceeds will be used to expand the company's healthcare product offering, relocate two healthcare clinics, and for general working capital. The company may pay finders' fees of up to 10% cash and 10% broker warrants. The private placement is subject to TSX Venture Exchange approval, and all issued securities will have a four-month and one-day hold period. The placement will not create a new control person, and the securities are not registered under the U.S. Securities Act.

Datametrex AI Limited (DTMXF) has completed the acquisition of Arbutus Health and Wellness Inc., a Vancouver-based multidisciplinary medical clinic. The acquisition was executed through a share exchange agreement dated June 5, 2025, where Datametrex acquired 100% of Arbutus Health's shares in exchange for 11 million common shares at $0.10 per share, valued at $1.1 million. Arbutus Health offers various healthcare services including walk-in services, family medicine, and skin laser treatments in a single location. The transaction, which requires final TSXV approval, will not result in any debt assumption, fundamental change, or change of control for Datametrex. The acquisition aligns with Datametrex's strategy to expand its healthcare sector presence.

Datametrex AI (DTMXF) has signed a non-binding Letter of Intent to acquire Arbutus Health and Wellness Inc., a Vancouver-based multidisciplinary medical clinic, for $1.1 million. The acquisition will be completed through the issuance of common shares at $0.10 per share.

Arbutus Health provides walk-in services, family medicine, skin laser treatments, and specialty healthcare services in a single location. The transaction requires customary closing conditions, definitive agreements, and regulatory approvals.

In a separate announcement, Richard Yoon has resigned from the Board of Directors effective March 28, 2025, with the company initiating a search for his replacement.

Datametrex AI (DTMXF) has announced a strategic restructuring plan focusing on healthcare and AI businesses. The company plans to expand its healthcare operations through M&A, targeting clinic acquisitions to provide family medicine, walk-in examinations, and specialist care. The expansion includes wellness services like IV therapy, Botox, and laser treatments.

As part of its 'deep and narrow' strategy, Datametrex will discontinue non-core operations in pharmacy and mobile gaming. The company reports strong cash flows from its AI service operations and aims to optimize AI solutions while exploring new partnerships.

A significant corporate restructuring is planned to split the company into two separate entities, focusing independently on healthcare and AI operations, aimed at enhancing operational efficiency and shareholder value.